Get the Stockscreener App
26.34
1.97%
0.49
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $26.34, with a volume of 26.16M.
It is up +1.97% in the last 24 hours and up +5.19% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.85
Open:
$25.82
24h Volume:
26.16M
Relative Volume:
0.39
Market Cap:
$149.79B
Revenue:
$62.79B
Net Income/Loss:
$9.84B
P/E Ratio:
15.35
EPS:
1.7156
Net Cash Flow:
$10.38B
1W Performance:
+2.29%
1M Performance:
+5.19%
6M Performance:
+7.42%
1Y Performance:
+3.05%
1-Day Range:
$25.81
$26.39
1-Week Range:
$25.13
$26.39
52-Week Range:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.34 | 146.98B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,055.31 | 919.64B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
213.79 | 509.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.41 | 394.69B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
134.28 | 254.37B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.36 | 248.95B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research - Reuters
Adaptive Biotechnologies inks two agreements with Pfizer in immunology By Investing.com - Investing.com UK
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M - Investing.com Canada
Adaptive Biotechnologies announces two immune receptor licensing agreements with Pfizer - PharmaLive
Adaptive Biotechnologies signs two immune receptor licensing deals with Pfizer - marketscreener.com
Watts Gwilliam & Co. LLC Buys 50,744 Shares of Pfizer Inc. $PFE - MarketBeat
Adaptive Biotechnologies Signs Target Discovery, Licensing Deals With Pfizer - marketscreener.com
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - marketscreener.com
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer - Yahoo Finance
Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025) - ts2.tech
Pfizer’s Hold Rating: Navigating Loss of Exclusivity and Flat Growth Prospects - TipRanks
47,996 Shares in Pfizer Inc. $PFE Acquired by MASTERINVEST Kapitalanlage GmbH - MarketBeat
Marex Group plc Purchases Shares of 65,461 Pfizer Inc. $PFE - MarketBeat
Will Dogecoin Reach $1 By the End of the Year? - The Motley Fool
Cullen Capital Management LLC Has $88.32 Million Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next - ts2.tech
Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks - ts2.tech
Pfizer’s New Phase 1 Study: A Potential Breakthrough for Kidney Disease Treatment - TipRanks
Orion Porfolio Solutions LLC Has $17.19 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025) - ts2.tech
Evergreen Capital Management LLC Purchases 63,611 Shares of Pfizer Inc. $PFE - MarketBeat
Forget Teladoc and Buy This Healthcare Stock Instead - Yahoo Finance
Bellevue Group AG Reduces Holdings in Pfizer Inc. $PFE - MarketBeat
Banque Transatlantique SA Lowers Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open - ts2.tech
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open - ts2.tech
Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026 - marketscreener.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 - Investing.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 By Investing.com - Investing.com Canada
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. - The Globe and Mail
Pfizer Declares First-Quarter 2026 Dividend - Business Wire
The Best Turnaround Stock to Invest $1,000 in Right Now - Finviz
Is Pfizer Shifting From Defensive Stock To Value Opportunity After Post Pandemic Restructuring? - simplywall.st
Treasurer of the State of North Carolina Purchases 520,580 Shares of Pfizer Inc. $PFE - MarketBeat
Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial - Reuters
NewEdge Advisors LLC Acquires 97,789 Shares of Pfizer Inc. $PFE - MarketBeat
Morgan Stanley Adjusts Price Target on Pfizer to $28 From $32, Maintains Equalweight Rating - marketscreener.com
CIBC Asset Management Inc Trims Stock Position in Pfizer Inc. $PFE - MarketBeat
Camber Capital Management LP Has $36.36 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. - Britannica
Bayesian Capital Management LP Sells 55,000 Shares of Pfizer Inc. $PFE - MarketBeat
Elevance Health Adds Former Pfizer GC To Its Board - Law360
Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield - ts2.tech
Ex-Pfizer executive joins Elevance’s board as insurer pursues pharmacy experience - Healthcare Dive
Pfizer plans job cuts in Switzerland to reduce expenses - Yahoo Finance
Down 50%, should you buy the dip on Pfizer? - MSN
Pfizer Inc. (PFE) Announces Results from Phase 3 BASIS Study - Finviz
Pfizer Inc. $PFE Shares Sold by Schwerin Boyle Capital Management Inc. - MarketBeat
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):